← Leaderboards
Jon Mirsalis
Sri International
$56,020,705
Attributed
$56,020,705
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $13.4M · FY2011–25$20M$15M$10M$5M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$56,020,705 · 5
By mechanism
N01$55,346,498 · 4
N02$674,207 · 3
Top collaborators
No co-investigators on record.
Most similar at Sri International
Same institution · by research overlap
- Jon Carl Mirsalis$108,012,322
- Jon Mirasilas$3,865,057
- John Mirsalis$5,655,148
- Mary Bastida$1,457,758
- Leanne Chan$6,246,253
Others in their field
Top investigators on “Services”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,236,423,805
- Leonard Freedman · Leidos Biomedical Research, Inc.$868,224,440
- Larry Arthur$689,089,782
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Bambra Strokes · Ppd Development Lp$526,656,217
- Mitchell J Malone · Texas A&M Research Foundation$353,400,900
Research focus
ServicesDevelopment PlansIn VitroToxicologyIn VivoEvaluationTherapeutic DevelopmentChemistryLeadPathogenToxinCommunicable DiseasesProgramsPre-ClinicalDrug KineticsInterventional Agent DevelopmentSafetyProduct DevelopmentMicrobiologySupport ContractsPreclinical SafetyAntimicrobial ResistanceImageHypersensitivity Skin Testing
Grant awards (74)
Task C13: GMP Manufacturing of Oxfendazole Clinical Trial Material and Stability Study$72,349
N01 · FY2025 · AI · contact PI
Task D02: Pre-Clinical Pharmacokinetic Services$1,871
N01 · FY2025 · AI · contact PI
Task B06: PROCESS DEVELOPMENT AND SYNTHESIS OF A THERAPEUTIC FOR LASSA FEVER VIRUS$1,004
N01 · FY2025 · AI · contact PI
Task D18: Non-Clinical Services for Development of Interventional Agents for Infectious Diseases$452,091
N01 · FY2024 · AI · contact PI
Task C13: GMP Manufacturing of Oxfendazole Clinical Trial Material and Stability Study$64,618
N01 · FY2024 · AI · contact PI
Task Order D14: Preclinical, Microbiological, Safety, Toxicology, and Pharmacokinetic Services$4,750,329
N01 · FY2023 · AI · contact PI
Task Order D-13 PRE-CLINICAL MICROBIOLOGICAL, SAFETY, TOXICOLOGY, AND PHARMACOKINETIC SERVICES$2,272,027
N01 · FY2023 · AI · contact PI
Task C08: Manufacturing of formulation platform of metronidazole for treating for treating Clostridium difficile infection$432,944
N01 · FY2023 · AI · contact PI
Task C13: GMP manufacturing of Oxfendazole clinical trial material and stability study$116,854
N01 · FY2023 · AI · contact PI
Task D06: Nonclinical Microbiological, Safety, Toxicology, and Pharmacokinetic Services$2,666,685
N01 · FY2022 · AI · contact PI
Task C19: Recertification for clinical use of GMP Product$157,734
N01 · FY2022 · AI · contact PI
Task C15: APP SYNTHESIS OF YELLOW FEVER COMPOUNDS$122,395
N01 · FY2022 · AI · contact PI
TASK A06: DEVELOPMENT OF A PRECLINICAL NEPHROTOXICITY SCREENING PLAN$49,839
N02 · FY2022 · AI · contact PI
Task A03: Nonclinical Service Training$32,055
N01 · FY2022 · AI · contact PI
Task Order 1: The Interventional Agent Development Services Program$82
N01 · FY2022 · AI · contact PI
Task D06: Nonclinical Microbiological, Safety, Toxicology, and Pharmacokinetic Services$2,631,694
N01 · FY2021 · AI · contact PI
Task D07: GLP 28-day repeat toxicology and cardiovascular telemetry assessment of Lassa antiviral in cynomolgus macaques$1,766,053
N01 · FY2021 · AI · contact PI
Task D06: Nonclinical Microbiological, Safety, Toxicology, and Pharmacokinetic Services$438,501
N01 · FY2021 · AI · contact PI
Task C13: GMP manufacturing of Oxfendazole clinical trial material and stability study$381,002
N01 · FY2021 · AI · contact PI
Formulation Development and Clinical Manufacturing: Manufacture of TLC-ART101 Bulk Product for Clinical Trials$294,778
N01 · FY2021 · AI · contact PI
Task D06: Nonclinical Microbiological, Safety, Toxicology, and Pharmacokinetic Services$282,904
N01 · FY2021 · AI · contact PI
Task B19: Synthesis of LpxC Inhibitors with Improved Physicochemical Properties$257,054
N01 · FY2021 · AI · contact PI
TASK C12: INVESTIGATION AND OPTIMIZATION OF PRECLINICAL THERAPEUTIC FORMULATIONS AGAINST RESISTANT BACTERIA$237,574
N01 · FY2021 · AI · contact PI
Task D06: Nonclinical Microbiological, Safety, Toxicology, and Pharmacokinetic Services$127,307
N01 · FY2021 · AI · contact PI
Task C08: Manufacturing of a colon-delivery formulation platform of metronidazole for treating Clostridium difficile infection$115,067
N01 · FY2021 · AI · contact PI
TISSUE CROSS-REACTIVITY STUDY OF A HUMAN ANTIBODY$107,538
N02 · FY2021 · CA · contact PI
Task A03: Nonclinical Service Training$78,482
N01 · FY2021 · AI · contact PI
Task A5: Update of Generic Product Development Plan$40,021
N01 · FY2021 · AI · contact PI
Preclinical Services for HIV Therapeutics: QA/QC Plan and Task Order Initiation Meeting$29,391
N01 · FY2021 · AI · contact PI
Task D06: Nonclinical Microbiological, Safety, Toxicology, and Pharmacokinetic Services$3,764,867
N01 · FY2020 · AI · contact PI
Task D05: Nonclinical Services for the Development of Interventional Agents for Infectious Diseases$3,657,861
N01 · FY2020 · AI · contact PI
Task C08: Manufacturing of a colon-delivery formulation platform of metronidazole for treating Clostridium difficile infection$1,575,447
N01 · FY2020 · AI · contact PI
Preclinical Development Services for AIDS Therapeutics: Pharmacology and Toxicology$1,314,501
N01 · FY2020 · AI · contact PI
Task D06: Nonclinical Microbiological, Safety, Toxicology, and Pharmacokinetic Services$806,758
N01 · FY2020 · AI · contact PI
Formulation Development and Clinical Manufacturing: Manufacture of TLC-ART101 Bulk Product for Clinical Trials$785,631
N01 · FY2020 · AI · contact PI
Task D05: Nonclinical Services for the Development of Interventional Agents for Infectious Diseases$400,000
N01 · FY2020 · AI · contact PI
Task D05: Nonclinical Services for the Development of Interventional Agents for Infectious Diseases$384,033
N01 · FY2020 · AI · contact PI
Task D06: Nonclinical Microbiological, Safety, Toxicology, and Pharmacokinetic Services$268,919
N01 · FY2020 · AI · contact PI
Preclinical Development Services for AIDS Therapeutics$246,142
N01 · FY2020 · AI · contact PI
Task D05: Nonclinical Services for the Development of Interventional Agents for Infectious Diseases$107,641
N01 · FY2020 · AI · contact PI
Task B11: Polymorph characterization and salt screening of a potential therapeutic for gram negative bacteria$40,208
N01 · FY2020 · AI · contact PI
Task B06: PROCESS DEVELOPMENT AND SYNTHESIS OF A THERAPEUTIC FOR LASSA FEVER VIRUS$7,489
N01 · FY2020 · AI · contact PI
Task D03: Pre-Clinical Microbiological and Safety Studies$1,698,255
N01 · FY2019 · AI · contact PI
Reproductive Toxicology Studies of Elsulfavirin with Toxicokinetics in Rats, and to Support the Development of Mitochondrial Toxicity Assays and Sample Analysis for Mitochondrial Toxicity Assessment$1,162,805
N01 · FY2019 · AI · contact PI
Preclinical Development Services for AIDS Therapeutics$120,038
N01 · FY2019 · AI · contact PI
Task B06: PROCESS DEVELOPMENT AND SYNTHESIS OF A THERAPEUTIC FOR LASSA FEVER VIRUS$109,630
N01 · FY2019 · AI · contact PI
Preclinical Development Services for AIDS Therapeutics$1,806,515
N01 · FY2018 · AI · contact PI
Task Order 1: The Interventional Agent Development Services Program$666,644
N01 · FY2018 · AI · contact PI
Task 11: Interventional Agent Development Services Program$412,093
N01 · FY2018 · AI · contact PI
Task 11: Interventional Agent Development Services Program$176,611
N01 · FY2018 · AI · contact PI
Task 11: Interventional Agent Development Services Program$3,017,090
N01 · FY2017 · AI · contact PI
Task 11: Interventional Agent Development Services Program$2,500,139
N01 · FY2017 · AI · contact PI
Task 11: Interventional Agent Development Services Program$1,580,085
N01 · FY2017 · AI · contact PI
PHARMACOLOGY AND TOXICOLOGY STUDIES OF AMIKACIN, TLC-ART-101, NDB-COMPOUNDS, SUTEZOLID, AND SUPPORT THE DEVELOPMENT OF MITOCHONDRIAL TOXICITY ASSAYS$1,439,619
N01 · FY2017 · AI · contact PI
Task 11: Interventional Agent Development Services Program$949,290
N01 · FY2017 · AI · contact PI
TO X9: OPTIMIZATION PK STUDIES$697,838
N01 · FY2017 · AI · contact PI
Task 4: The Interventional Agent Development Services Program$381,000
N01 · FY2017 · AI · contact PI
TO X9: OPTIMIZATION PK STUDIES$284,966
N01 · FY2017 · AI · contact PI
Task 11: Interventional Agent Development Services Program$284,619
N01 · FY2017 · AI · contact PI
Task 11: Interventional Agent Development Services Program$284,619
N01 · FY2017 · AI · contact PI
Task Order 1: The Interventional Agent Development Services Program$219,967
N01 · FY2017 · AI · contact PI
TO X9: OPTIMIZATION PK STUDIES$193,766
N01 · FY2017 · AI · contact PI
Task 4: The Interventional Agent Development Services Program$91,300
N01 · FY2017 · AI · contact PI
IGF::OT::IGF PHARMACOLOGY AND TOXICOLOGY STUDIES OF AMIKACIN AND SUTEZOLID, AND SUPPORT THE DEVELOPMENT OF BIOMARKER AND MITOCHONDRIAL TOXICITY ASSAYS.$2,005,107
N01 · FY2016 · AI · contact PI
Task X10: Preclinical Services for the Development of Therapeutics against Antimicrobial Resistant Organisms$605,471
N01 · FY2016 · AI · contact PI
TO X9: OPTIMIZATION PK STUDIES$589,837
N01 · FY2016 · AI · contact PI
Task Order 1: The Interventional Agent Development Services Program$574,703
N01 · FY2016 · AI · contact PI
Task 4: The Interventional Agent Development Services Program$481,426
N01 · FY2016 · AI · contact PI
IGF::OT::IGF PHARMACOKINETIC (PK) STUDY IN MICE WITH THREE ANTIRETROVIRAL AGENTS: SN38-LACTAM, 05-9A, AND 02-16.$197,953
N01 · FY2016 · AI · contact PI
Task 4: The Interventional Agent Development Services Program$154,868
N01 · FY2016 · AI · contact PI
TO X9: OPTIMIZATION PK STUDIES$147,459
N01 · FY2016 · AI · contact PI
Task Order 1: The Interventional Agent Development Services Program$537,730
N01 · FY2015 · AI · contact PI
Task Order 1: The Interventional Agent Development Services Program$516,830
N02 · FY2014 · AI · contact PI
Task 6:NIAID Preclinical Services for the Development of Interventional Agents$792,692
N01 · FY2011 · AI · contact PI